Chugai Pharmaceutical Co., Ltd. and Roche Holding AG have announced additional results from the global Phase III COMMODORE 1 and 2 clinical trial program with crovalimab for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), on the basis of which the anti-C5 recycling monoclonal antibody has just been submitted for approval in Japan for this indication.
Crovalimab Filed In Japan As More Phase III Results Released At EHA
Potential Lower Dosing Time Benefit
The Chugai/Roche antibody has been filed for PNH in Japan as more details of its Phase III results are released.
More from Immunological
• By
The biotech is banking on itolizumab’s longer-term efficacy as well as unmet need in frontline acute graft-versus-host disease as it prepares to meet with the FDA.
• By
Kyoto-based venture moves HQ to California to expand R&D and business outreach for its regulatory T-cell technology, as it raises around $46m in public and private funding.
• By
Obefazimod has been heralded as a potential blockbuster for ulcerative colitis and there will be great interest in the readout of Phase III induction trials in the third quarter of this year.
• By
The development could highlight the power of competitive market forces over government price controls or suggest Medicare price negotiation is enhancing competitive market forces.
More from Therapy Areas
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
The ZENITH study is a landmark for Merck’s first-in-class activin signalling inhibitor and pulmonary arterial hypertension treatment.
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.